VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
- Resource Type
- Source
- Annals of Oncology. 33:114-116
- Subject
Sorafenib Oncology medicine.medical_specialty Cabozantinib business.industry First line Hematology medicine.disease chemistry.chemical_compound chemistry Atezolizumab Hepatocellular carcinoma Internal medicine medicine business medicine.drug - Language
- ISSN
- 0923-7534